Fig. 3 | Scientific Reports

Fig. 3

From: Addition of bedtime lafutidine inhibits nocturnal acid-breakthrough and improves sleep quality in gastroesophageal reflux disease patients on esomeprazole: a randomized controlled trial

Fig. 3

The response rate of heartburn and regurgitation of patients with or without NAB. The response rates to treatment for daytime and nighttime heartburn and regurgitation symptoms showed no statistically significant differences between patients with and without NAB (p > 0.05). However, the treatment response rates for nighttime heartburn and regurgitation were numerically higher in patients without NAB. NAB: nocturnal acid-breakthrough

Back to article page